SRR8613796
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.520
- UV_RESPONSE_DN+0.360
- ESTROGEN_RESPONSE_LATE+0.350
- MYOGENESIS+0.310
- ANDROGEN_RESPONSE+0.230
- APICAL_SURFACE+0.230
- BILE_ACID_METABOLISM+0.230
- COAGULATION+0.220
- PANCREAS_BETA_CELLS+0.190
- TNFA_SIGNALING_VIA_NFKB+0.190
Top 10 suppressed
- E2F_TARGETS-0.710
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V1-0.580
- OXIDATIVE_PHOSPHORYLATION-0.460
- ALLOGRAFT_REJECTION-0.430
- MTORC1_SIGNALING-0.430
- MYC_TARGETS_V2-0.430
- DNA_REPAIR-0.390
- INTERFERON_ALPHA_RESPONSE-0.380
- MITOTIC_SPINDLE-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313113 | — | A | 0.920 |
| 2 | GSM6454739 | — | A | 0.891 |
| 3 | SRR25617932 | — | A | 0.876 |
| 4 | 20050067.LumA | — | A | 0.853 |
| 5 | SRR8518381 | — | A | 0.851 |
| 6 | C3N-02193 | — | cohortA1 | 0.850 |
| 7 | BSR_15_0097_A4_S88 | — | A | 0.849 |
| 8 | s0095205 | — | — | 0.848 |
| 9 | MNG330 | — | — | 0.844 |
| 10 | X9cad7a78.ea9b.47b0.9d06.e5e696031cc3 | — | cohortA1 | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.520 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.350 | Idelalisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.070 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.050 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |